E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Nasosinusal endoscopic surgery in patients with chronic sinusitis and/or nasal polyposis |
Cirugía endoscópica nasosinusal en pacientes con sinusitis crónica y/o poliposis nasal |
|
E.1.1.1 | Medical condition in easily understood language |
Nasosinusal endoscopic surgery |
Cirugía endoscópica nasosinusal |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Ear, nose and throat diseases [C09] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10009137 |
E.1.2 | Term | Chronic sinusitis |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028755 |
E.1.2 | Term | Nasal polypectomy |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare intraoperative bleeding during nasosinusal endoscopic surgery, in patients receiving treatment hypotensive anesthetic based on clonidine or dexmedetomidine as assessed through a modified Boezaart score for surgical field bleeding, evaluated by the external evaluator blinded to the identity of the treatments administered |
Comparar el sangrado del campo quirúrgico durante la cirugía endoscópica nasosinusal (CENS), en pacientes que reciben tratamiento anestésico hipotensivo basado en clonidina o en dexmedetomidina mediante la estimación realizada con la escala de Boezaart del sangrado del campo quirúrgico modificada, evaluada por el evaluador externo ciego a la identidad de los tratamientos administrados |
|
E.2.2 | Secondary objectives of the trial |
- Surgical field bleeding through the estimates of the amount of blood
aspirated during the intervention in mL, according to an hemoglobin
correction formula
- Surgical field bleeding through the subjective assessment of the
intensity of bleeding during surgery by the surgeon
- Surgical field bleeding through the subjective assessment of the
intensity of bleeding during surgery by an external observer blinded to
treatment identity
- Duration of the anesthesia and of the surgical procedure
- Complications post-procedure (hematoma or orbital emphysema,
cerebrospinal fluid leaks, heavy bleeding, etc.)
- Time to hospital discharge after surgery |
- Sangrado del campo quirúrgico mediante la estimación de la cantidad de sangre aspirada durante la intervención en mL, según fórmula de corrección de hemoglobina en aspirado.
- Sangrado del campo quirúrgico mediante la estimación de la intensidad del sangrado durante la cirugía por escalas subjetivas evaluadas por el cirujano.
- Sangrado del campo quirúrgico mediante la estimación de la intensidad del sangrado durante la cirugía por escalas subjetivas evaluadas por el evaluador externo ciego a la identidad de los tratamientos
- Duración de la cirugía CENS y de la anestesia correspondiente
- Complicaciones postoperatorias (hematoma o enfisema orbitarios,
fístulas de líquido cefalorraquídeo, sangrado copioso, etc)
- Tiempo hasta el alta del paciente |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients of age >18 and < 65 years old
2. Patients with ASA criteria I, II or III
3. Patients who will undergo nasosinusal endoscopic surgery
because of chronic infectious sinusitis and/or nasal polyposis
4. Patients providing their informed consent |
1. Pacientes mayores de 18 años y menores de 65 años.
2. Pacientes con criterios ASA I, II o III.
3. Pacientes que vayan a ser sometidos a CENS por patología sinusal crónica; primaria o secundaria, ya sea por poliposis nasal o por sinusopatía crónica infecciosa.
4. Pacientes que otorguen su consentimiento informado
|
|
E.4 | Principal exclusion criteria |
1. Patients who have contraindications to the intended nasosinusalendoscopic surgery or to the anaesthesic treatment used in the routine clinical practice of this type of surgery.
2. Patients with impaired coagulation or who are treated with
antiaggregants or anticoagulants.
3. Patients with antecedents of coronary arteriopathy or heart rhytm
diseases (tachyarhythmias or blockages).
4. Patients that at the time of surgery show signs of hypovolemia, severe hypotension or signs of heart failure.
5. Patients with previous cerebro-vascular event.
6. Patients with chronic treatment with beta-adrenergic blocker agents, or calcium channel blocking agents that have not been withdrawn for a wash-out period equivalent to at least 7 half-lives of the drug before the surgery.
7. Patients for whom their caring physician considers that participation in the study may be clinically detrimental. |
1. Pacientes con contraindicaciones para someterse a la intervención quirúrgica CENSo para someterse al tratamiento anestésico utilizado en el estudio para la CENS.
2. Pacientes con trastornos de la coagulación o que reciban tratamiento con medicamentos antiagregantes o anticoagulantes.
3. Pacientes con historia previa de arteriopatía coronaria o trastornos del ritmo (taquiarrítmias cardiacas o bloqueos).
4. Pacientes que en el momento de la intervención presenten signos de hipovolemia, hipotensión severa, o signos de insuficiencia cardíaca.
5. Antecedente de accidente vascular cerebral
6. Pacientes en tratamiento crónico con bloqueantes adrenérgicos o bloqueantes de los canales del calcio que en el momento de la intervención no hayan superado un periodo de blanqueo apropiado (mínimo de 7 semividas de eliminación).
7. Pacientes en los que se considere que la participación en el estudio puede suponer un perjuicio clínico, en opinión del médico responsable del cuidado del paciente. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the Boezaart bleeding score from the surgical field where Boezaart scale degrees are defined as follows:
Grade 1: cadaverous Conditions requiring minimum suction .
Grade 2 : Minimum unusual bleeding that requires suction.
Grade 3: Active bleeding that requires frequent suckling .
Grade 4: Bleeding covers the surgical field after removing the suction and before the instrument can be maneuvered .
Grade 5: uncontrolled bleeding . Bleeding outside the nostril to remove the suction.
An average score will be calculated for the scale of Boezaart at different times and reclassified into a dichotomous variable of scant bleeding ( ratings equal or below 2 ) and abundant bleeding (ratings greater than 2 ) for the primary analysis of the study. |
La variable principal será la escala de Boezaart de sangrado del campo quirúrgico, donde los grados de la escala Boezaart quedan definidos de la siguiente manera:
Grado 1: Condiciones cadavéricas que requieren de mínima succión.
Grado 2: Sangrado mínimo que requiere de succión infrecuente.
Grado 3: Sangrado activo que requiere de succión frecuente.
Grado 4: El sangrado cubre el campo quirúrgico después de retirar la succión y antes de que el instrumento pueda ser maniobrado.
Grado 5: Sangrado no controlado. Sangrado por fuera de la narina al retirar la succión.
Se realizará un promedio de la puntuación en la escala de Boezaart a distintos tiempos y se reclasificará en una variable dicotómica de sangrado escaso (puntuaciones iguales o inferiores a 2) y sangrado copioso (puntuaciones superiores a 2) para el análisis principal del estudio. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Every 60 minutes during the intervention |
Cada 60 minutos durante la intervención. |
|
E.5.2 | Secondary end point(s) |
-Intraoperative bleeding estimated in milliliters
-Assessment of bleeding by both the surgeon and a blind evaluator from the video recording of interventions, every 60 minutes, using the visual analogue scale (VAS ) intensity of the operative field bleeding
and the Boezaart scale
-Duration Surgery , defined as time from the start of the intervention by the surgeon to the nasal tampooning .
-Duration Anesthesia, defined as time from the start of induction to extubation of the patient.
-Evaluation of Lund - Mackay scale before surgery
-Postoperative surgical and anesthetic complications
-Duration of the hospital stay
-Assessment of bleeding and late complications of surgery at a follow-up outpatient visit one week after surgery.
|
-La estimación del sangrado intraoperatorio en mililitros
-Valoración del sangrado, tanto por el cirujano como por un evaluador ciego a partir de la grabación en video de las intervenciones, cada 60 minutos, mediante escalas:
o Escala analógica visual (EVA) de intensidad del sangrado del campo operatorio
o Escala de Boezaart
-Duración de la cirugía, definida como tiempo desde el inicio de la intervención por parte del cirujano hasta el taponamiento nasal.
-Duración de la anestesia, definida como tiempo desde el inicio de la inducción hasta la extubación del paciente.
-Valoración de la escala de Lund-Mackay previa a la cirugía
-Complicaciones postoperatorias, quirúrgicas y anestésicas
-Duración del ingreso hospitalario
-Evaluación en la visita de seguimiento ambulatoria al cabo de aproximadamente 1 semana del sangrado y/o complicaciones tardías postoperatorios. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
during the surgery |
Durante la intervención |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit |
Última visita del último paciente incluido |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |